Ascendis Pharma A (ASND) Current Deferred Revenue (2012 - 2026)

Ascendis Pharma A has reported Current Deferred Revenue for 14 years, with the latest figure at $5.8 million in Q4 2025.

• Quarterly Current Deferred Revenue rose 475.38% year-over-year to $5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 475.38% YoY) and the FY2025 annual result came in at $5.8 million, up 475.38% from the prior year.
• Current Deferred Revenue improved to $5.8 million in Q4 2025 per ASND's latest filing, from $4.9 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $16.2 million in Q3 2022 and troughed at $42454.3 in Q3 2021.
• A 5-year average of $3.3 million and a median of $1.6 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue soared 38136.88% in 2022, then sank 88.03% in 2024.
• Over 5 years, Current Deferred Revenue stood at $3.0 million in 2021, then jumped by 445.57% to $16.2 million in 2022, then tumbled by 92.15% to $1.3 million in 2023, then decreased by 21.49% to $1.0 million in 2024, then surged by 475.38% to $5.8 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $5.8 million, $4.9 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.